Aeglea Bio Therapeutics Inc (NASDAQ:AGLE) Director Anthony G. Quinn acquired 4,100 shares of Aeglea Bio Therapeutics stock in a transaction dated Friday, December 1st. The stock was purchased at an average cost of $4.53 per share, with a total value of $18,573.00. Following the completion of the purchase, the director now owns 14,100 shares of the company’s stock, valued at $63,873. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.
Shares of Aeglea Bio Therapeutics Inc (AGLE) traded up $0.03 during trading hours on Thursday, hitting $4.91. 62,815 shares of the company were exchanged, compared to its average volume of 65,900. Aeglea Bio Therapeutics Inc has a 12-month low of $2.81 and a 12-month high of $8.14.
Aeglea Bio Therapeutics (NASDAQ:AGLE) last issued its earnings results on Tuesday, November 7th. The biotechnology company reported ($0.48) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.55) by $0.07. Aeglea Bio Therapeutics had a negative net margin of 527.99% and a negative return on equity of 44.05%. The firm had revenue of $1.26 million during the quarter. analysts expect that Aeglea Bio Therapeutics Inc will post -1.97 EPS for the current year.
Separately, Zacks Investment Research raised shares of Aeglea Bio Therapeutics from a “hold” rating to a “buy” rating and set a $5.50 price objective for the company in a research note on Friday, November 10th.
About Aeglea Bio Therapeutics
Aeglea BioTherapeutics, Inc is a biotechnology company, which is engaged in the development of enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism (IEM) and cancer. The Company’s product pipeline includes AEB1102, AEB3103, AEB2109 and AEB4104. Its lead product candidate, AEB1102, is engineered to degrade the amino acid arginine and is being developed to treat over two extremes of arginine metabolism, including arginine excess in patients with Arginase I deficiency, an IEM, as well as some cancers, which have shown to have a metabolic dependence on arginine.
Receive News & Ratings for Aeglea Bio Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea Bio Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.